Certara, Inc.

Our Company is a global leader in biosimulation science, technology, and consulting services, focusing on Model-Informed Drug Development ("MIDD") for the global biopharmaceutical and biotech industry. MIDD uses biological and statistical models from preclinical, clinical, and evidence data to guide decisions in drug research, development, and commercialization. Biosimulation, a key part of MIDD, employs computer-aided mathematical simulations of biological processes and systems to understand how a drug acts in humans or populations. This approach can increase the likelihood of a new drug reaching the market, speed up its development, and lower costs. Biosimulation supports drug development from discovery, preclinical stages, first-in-human dose predictions, clinical trial simulations, and protocol design, to drug interaction label claims. It also helps after approval with formulation or manufacturing changes and label extensions. MIDD strategies are increasingly used to predict commercial success. The pharmaceutical industry spends over $290 billion annually on research and development. Developing one new medicine typically takes 10-15 years and costs $6.2 billion, including the cost of failures.